Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Results from MUSIC-HFpEF Phase 1/2a clinical trial show favorable safety profile and early clinical benefits with SRD-002 gene therapy BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Medera Inc....
-
BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation...
-
BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation...
-
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of...
-
BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a...
-
Cutting-Edge Cardiac Research: Novoheart’s CTScreen™ system has been installed at UMC Utrecht, equipping Regenerative Medicine Center with advanced high-throughput tools to accelerate human cardiac...
-
SUMMIT, N.J. and BOSTON, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Medera, Inc., (“Medera”), a clinical-stage biotechnology company, announced today that the management team will participate in the two...
-
Innovative Technology Integration: The strategic partnership seamlessly integrates the unique ability of Novoheart’s human "Heart-in-a-Jar" to assess cardiac pump performance with Curi Bio’s...
-
Innovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular therapiesFeatures improved automation, environmental control, and flexible testing...
-
Medera and Cardiovascular Disease National Collaborative Enterprise (CADENCE) announce the initiation of Asia's first cardiac gene therapy clinical trial for heart failure, with Singapore being the...